MMP and Protease Balance in Chronic Wounds: What to Know

MMP and Protease Balance: Why Chronic Wounds Self-Destruct

Matrix metalloproteinases (MMPs) and protease balance represent one of the most clinically actionable concepts in chronic wound biology. In normal wound healing, MMPs are essential — they clear damaged extracellular matrix, facilitate cell migration, and enable tissue remodeling. The problem arises when MMP activity exceeds the capacity of their natural inhibitors (TIMPs), creating a biochemical environment where new tissue is degraded as fast as it is built. This protease imbalance is present in virtually every chronic wound that fails to progress, and addressing it is often the intervention that unlocks stalled healing.

The Normal Role of MMPs in Wound Healing

MMPs are a family of over 25 zinc-dependent endopeptidases that collectively can degrade every component of the extracellular matrix. In wound healing, their activity is precisely regulated in both timing and location.

Specific MMPs and Their Functions

MMP-1 (collagenase-1) cleaves fibrillar collagens (types I, II, III), enabling keratinocyte migration across the wound surface during epithelialization. Without MMP-1, keratinocytes cannot dissect through the collagen matrix at the wound edge.

MMP-2 (gelatinase A) and MMP-9 (gelatinase B) degrade denatured collagen (gelatin), type IV collagen in basement membranes, and elastin. They facilitate cell migration through basement membranes and are essential for angiogenesis — endothelial tip cells use MMP-2 and MMP-9 to penetrate the extracellular matrix during vessel sprouting.

MMP-8 (collagenase-2, neutrophil collagenase) is released primarily by neutrophils. It is the most abundant MMP in chronic wound fluid and the primary driver of pathological collagen degradation.

MMP-3 (stromelysin-1) has broad substrate specificity and activates other pro-MMPs, functioning as an amplifier of overall protease activity.

Regulation by TIMPs

Tissue inhibitors of metalloproteinases (TIMP-1 through TIMP-4) bind MMPs in a 1:1 ratio and neutralize their activity. In normal wound healing, TIMP levels rise and fall in coordination with MMP activity, maintaining a balance that allows controlled matrix remodeling without runaway degradation.

How Protease Imbalance Develops in Chronic Wounds

Chronic wounds shift from controlled MMP activity to sustained protease excess through several reinforcing mechanisms.

The Inflammatory Feedback Loop

Persistent bacterial burden — particularly biofilm — maintains a chronic inflammatory state. Neutrophils and macrophages recruited to fight bacteria release MMP-8, MMP-9, and neutrophil elastase into the wound environment. Because the biofilm is not eradicated by this inflammatory response, the recruitment continues indefinitely, and MMP levels remain elevated. For strategies to break this cycle, see our guide on biofilm management in wound care.

Growth Factor Destruction

The same proteases that degrade the extracellular matrix also degrade growth factors. PDGF, VEGF, TGF-beta, and EGF are all MMP substrates. This means that in high-protease environments, both endogenous growth factors and exogenous growth factors applied as therapy are rapidly inactivated. This is why applying growth factor products to wounds with uncontrolled protease activity often produces no clinical benefit — the growth factors are destroyed before they can act.

Senescent Fibroblasts

Fibroblasts in chronic wound environments become phenotypically altered — they produce less collagen, respond poorly to growth factor stimulation, and in some cases produce elevated MMPs themselves. This creates a situation where even the cells responsible for matrix synthesis contribute to matrix destruction.

Quantifying the Imbalance

Research consistently shows that chronic wound fluid has MMP activity 10 to 100 times higher than acute wound fluid. MMP-8 levels in non-healing wounds are typically 5 to 10 times higher than in healing wounds. TIMP-1 levels may be normal or even slightly elevated, but they are overwhelmed by the magnitude of MMP excess.

Clinical Detection of Elevated Protease Activity

Clinical Signs

Not all protease excess is clinically obvious, but several wound characteristics correlate with elevated MMP activity:

Friable granulation tissue that bleeds easily and appears glassy or translucent rather than beefy red
Stalled wound healing despite adequate perfusion, nutrition, and offloading — the wound generates granulation tissue but does not progress to epithelialization
Persistent moderate-to-high exudate with a thin, watery quality
Wound bed regression — wound area increasing or depth recurring after initial improvement

Point-of-Care Testing

Several point-of-care protease test kits are commercially available. These tests use wound fluid or wound swab samples and provide semiquantitative results for elevated protease activity (typically elevated MMP or neutrophil elastase) within minutes. They help identify wounds that would benefit from protease-modulating therapy and can guide treatment decisions when clinical signs are ambiguous.

Protease-Modulating Therapies

Collagen-Based Dressings

Collagen dressings function as sacrificial substrates — MMPs bind to and degrade the exogenous collagen instead of the endogenous wound bed matrix. This is not a permanent solution, but it provides a window of reduced protease burden during which the wound can begin producing and retaining its own matrix. The dressing must be changed regularly because the collagen is consumed by protease activity.

Oxidized Regenerated Cellulose (ORC) / Collagen Products

ORC/collagen dressings (such as Promogran) combine collagen with oxidized regenerated cellulose, which binds and inactivates MMPs and neutrophil elastase while also binding and protecting growth factors from protease degradation. Clinical studies have demonstrated faster healing in diabetic foot ulcers treated with ORC/collagen compared to moist wound healing alone.

Addressing Upstream Causes

Protease-modulating dressings treat the symptom. Addressing the cause requires managing the inflammatory drivers:

Biofilm disruption through aggressive debridement and antimicrobial strategies reduces the inflammatory stimulus that drives MMP production
Wound bed preparation following the TIME framework systematically addresses each barrier to healing, including protease imbalance — see wound bed preparation
Infection control — treating clinical infection reduces neutrophil influx and associated MMP release
Optimizing systemic factors — glycemic control, nutrition, smoking cessation — reduces the systemic contributions to elevated inflammation

Key Takeaways

MMPs are essential for normal wound healing but become destructive when their activity exceeds TIMP inhibition — a condition present in virtually all chronic wounds.
MMP-8 (neutrophil collagenase) is the primary pathological protease in chronic wounds, driven by sustained inflammatory cell recruitment in response to biofilm and persistent bacterial burden.
Elevated protease activity destroys both the extracellular matrix and growth factors, explaining why growth factor therapy and ECM products fail in wounds with uncontrolled MMP activity.
Collagen and ORC/collagen dressings provide temporary protease modulation by acting as sacrificial substrates, but sustained benefit requires addressing the inflammatory cause — typically biofilm.
Point-of-care protease tests can identify elevated MMP activity when clinical signs are ambiguous, guiding the decision to add protease-modulating therapy.